

AUG 31 2006

FAX NO.: 571/273-8300

Atty Docket No. 181 US UT01

**OFFICIAL COMMUNICATION FOR THE ATTENTION OF
THE U.S. PATENT AND TRADEMARK OFFICE**

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application No. 10/676,476, filed September 30, 2003, are being facsimile transmitted to the United States Patent and Trademark Office, on the date shown below.

Documents Attached

1. Transmittal Form-PTO/SB/21 (1 page)
2. Response to Notice of Non-Compliant Amendment (6 pages)
3. Copy of Notice of Non-Compliant Amendment (1 page)

Number of pages being transmitted, including this page: 9

Dated: aug. 31, 2006 Linda Pete
Linda Pete

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (510) 574-1473**

PDL BIOPHARMA, INC.
34801 Campus Drive
Fremont, CA 94555
Telephone: 510/574-1400
Customer No.: 47470

AUG 31 2006

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/676,476
	Filing Date	September 30, 2003
	First Named Inventor	DuBridge
	Art Unit	1636
	Examiner Name	J. A. Dunston
Total Number of Pages in This Submission	9	Attorney Docket Number
		181 US UT01

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Response to Notice of Non-Compliant Amendment Under 37 CFR 1.121 and copy of Notice
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm or Individual name	Renee M. Kossiak, Reg. No. 47,717, PDL BioPharma, Inc.
Signature	<i>Renee M. Kossiak</i>
Date	August 31, 2006

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO (Facsimile No. 571-273-8300) or deposited with the United States Postal Service with sufficient postage as Express mail (Label No.) in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 31, 2006	
Typed or printed name	Linda Pete
Signature	<i>Linda Pete</i>
Date	August 31, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

AUG 31 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DuBridge	Docket No: 181 US UT01
Serial No.: 10/676,476	Confirmation No.: 7526
Filed: September 30, 2003	Group Art Unit: 1636
For: EFFICIENT GENERATION OF STABLE EXPRESSION CELL LINES THROUGH THE USE OF SCORABLE HOMEOSTATIC REPORTER GENES	Examiner: Dunston, J. A.

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant has considered the Notice of Non-Compliant Amendment mailed August 24, 2006, and submits a complete listing of the claims on or before September 24, 2006.

Amendments to the Claims begin at page 2 of this paper.

Remarks begin at page 6 of this paper.